New Injectable Focus of HIV PrEP Clinical Trial

    loading  Checking for direct PDF access through Ovid

Abstract

A Phase III study will determine whether a long-acting form of an anti-HIV drug injected once every eight weeks can safely protect people from HIV infection at least as well as a combination of anti-HIV medications taken daily as an oral tablet.

Related Topics

    loading  Loading Related Articles